Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

ClinicalTrials.gov ID: NCT00529568

Public ClinicalTrials.gov record NCT00529568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Study identification

NCT ID
NCT00529568
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
759 participants

Conditions and interventions

Interventions

  • eltrombopag Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2007
Primary completion
Jul 31, 2011
Completion
Jul 31, 2011
Last update posted
Nov 4, 2013

2007 – 2011

United States locations

U.S. sites
59
U.S. states
26
U.S. cities
52
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294-0005
GSK Investigational Site Tucson Arizona 85750
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Arcadia California 91007
GSK Investigational Site La Jolla California 92037
GSK Investigational Site Los Angeles California 90017
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Lynwood California 90262
GSK Investigational Site Sacramento California 95817
GSK Investigational Site San Clemente California 92673
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Mateo California 94403
GSK Investigational Site Aurora Colorado 80045
GSK Investigational Site New Haven Connecticut 06510
GSK Investigational Site Washington D.C. District of Columbia 20010
GSK Investigational Site Washington D.C. District of Columbia 20307
GSK Investigational Site Bradenton Florida 34209
GSK Investigational Site Jacksonville Florida 32207
GSK Investigational Site Miami Florida 33125
GSK Investigational Site Honolulu Hawaii 96817
GSK Investigational Site Chicago Illinois 60612-3824
GSK Investigational Site Indianapolis Indiana 46202
GSK Investigational Site Lexington Kentucky 40536
GSK Investigational Site New Orleans Louisiana 70112
GSK Investigational Site Boston Massachusetts 02215
GSK Investigational Site Burlington Massachusetts 01805
GSK Investigational Site Worcester Massachusetts 01655
GSK Investigational Site Detroit Michigan 48201
GSK Investigational Site Detroit Michigan 48202
GSK Investigational Site Jackson Mississippi 39202
GSK Investigational Site St Louis Missouri 63104
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Lebanon New Hampshire 03756
GSK Investigational Site Manhasset New York 11030
GSK Investigational Site New York New York 10016
GSK Investigational Site New York New York 10021
GSK Investigational Site Rochester New York 14642
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site The Bronx New York 10468
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Durham North Carolina 27710
GSK Investigational Site Kinston North Carolina 28501
GSK Investigational Site Morganton North Carolina 28655
GSK Investigational Site Tulsa Oklahoma 74104
GSK Investigational Site Portland Oregon 97239
GSK Investigational Site Hershey Pennsylvania 17033-0850
GSK Investigational Site Philadelphia Pennsylvania 19104
GSK Investigational Site Germantown Tennessee 38138
GSK Investigational Site Mountain Home Tennessee 37684
GSK Investigational Site Nashville Tennessee 37203
GSK Investigational Site Nashville Tennessee 37205
GSK Investigational Site Nashville Tennessee 37212
GSK Investigational Site Dallas Texas 75203
GSK Investigational Site Galveston Texas 77555-0435
GSK Investigational Site Houston Texas 77030
GSK Investigational Site San Antonio Texas 78215
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Richmond Virginia 23249
GSK Investigational Site Seattle Washington 98111

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 168 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00529568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2013 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00529568 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →